XML 71 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborations and Other Arrangements (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues $ 28,541.4 $ 28,318.4 $ 24,539.8
Olumiant®      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues $ 830.5 1,115.1 638.9
Olumiant® | Royalty Payments Received      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative arrangement, rights and obligations percent (up to) 20.00%    
Olumiant® | Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Potential achievements $ 330.0 260.0  
Olumiant® | Milestone Payments, Development and Regulatory      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Potential achievements 100.0    
COVID-19 Antibodies      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues 2,020.0 $ 2,240.0 $ 871.2
Lebrikizumab | Milestone Payments, Development and Regulatory      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Potential achievements 65.0    
Lebrikizumab | Milestone Payments, Development and Regulatory | Roche      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Potential achievements 165.0    
Lebrikizumab | Milestone Payments, Sales-based      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Potential achievements 1,250.0    
Lebrikizumab | Milestone Payments, Sales-based | Roche      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Potential achievements $ 1,030.0